Ortiz Arduan A, Gutiérrez J R, Méndez A, Ortiz A
Rev Clin Esp. 1989 Jun;185(1):41-3.
The current status of immunosuppression in renal transplants is reviewed: non-specific (corticosteroids and cytostatics), lymphocyte-specific (polyclonal antilymphocyte globulin), T-specific (cyclosporine, antithymocyte polyclonal gamma globulin) with special attention to the OKT3 and monoclonal antibodies. Supported by the current experience of the use of PAN-T (OKT3) antiidiotypic monoclonal antibodies in the graft rejection treatment, a hypothesis is elaborated--feasible to demonstrate--to determine what would happen if anti-clonotypic monoclonal antibodies (the idiotypes of T lymphocytes) are used when looking for a specific immunosuppression. We conclude that the immunosuppression with anti-idiotypes, if it is confirmed, would be almost ideal.
非特异性(皮质类固醇和细胞抑制剂)、淋巴细胞特异性(多克隆抗淋巴细胞球蛋白)、T细胞特异性(环孢素、抗胸腺细胞多克隆γ球蛋白),并特别关注OKT3和单克隆抗体。基于目前使用PAN-T(OKT3)抗独特型单克隆抗体治疗移植排斥反应的经验,阐述了一个假设——可证明该假设可行——以确定在寻求特异性免疫抑制时使用抗克隆型单克隆抗体(T淋巴细胞的独特型)会发生什么。我们得出结论,如果抗独特型免疫抑制得到证实,将几乎是理想的。